Clinical Trial Update: Study of Lacutamab in Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating lacutamab for Peripheral T-cell lymphoma (including relapsed/recurrent disease) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Lacutamab (lacutamab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Peripheral T Cell Lymphoma, Relapse/Recurrence | Phase 2 | Status: RECRUITING